Monitor the conference presentation and any subsequent press releases for potential business updates or strategic announcements. No immediate trading action warranted based on this filing alone.
Drugs in focus
KMDA drug pipeline →CYTOGAM
● Neutral Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already FDA-approved and commercially marketed
- Next catalyst
- None dated
What to watchCYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 10 $7.99entry
- T+1 · 2mo ago −0.88%α −1.73% · $7.92
- T+5 · 2mo ago +8.51%α +9.01% · $8.67
- T+20 · 6w ago −2.69%α −4.82% · $7.78
- T+47 · todayOpen
- T+60 · in 17d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kamada announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. This is a routine investor relations event with no new material financial or operational data disclosed. The filing provides no financial figures, guidance, or business updates beyond the conference participation.
Key Facts
- CEO Amir London to present at H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026 at 2:30 PM ET.
- One-on-one investor meetings will be available throughout the conference.
- No financial results, guidance, or material business developments were disclosed in this filing.
Financial Impact
No financial impact, routine conference participation announcement only.
Risk Factors
- No material risks disclosed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (KMDA), Batch item 1 | 0001213900-26-098574 |
| Document: ea030509101ex99-1.htm | 0001213900-26-098574 |
| Document: 0001213900-26-098574-index-headers.html | 0001213900-26-098574 |
| Document: 0001213900-26-098574-index.html | 0001213900-26-098574 |
| Document: 0001213900-26-098574.txt | 0001213900-26-098574 |
| 6-K Filing (KMDA), Batch item 6 | 0001213900-26-098574 |
| Document: ea030509101ex99-1.htm | 0001213900-26-098574 |
| Document: 0001213900-26-098574-index-headers.html | 0001213900-26-098574 |
| Document: 0001213900-26-098574-index.html | 0001213900-26-098574 |
| Document: 0001213900-26-098574.txt | 0001213900-26-098574 |
Track record
25 reports on KMDA
8 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 No price data
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
- Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
- Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
- Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
- Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
- Sep 10, 20269w ago 6-K Neutral 2/10 Viewing Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
- Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers